News

NICE Recommends First Vitiligo Treatment for Use in the NHS

Badari Andukuri

24 hours ago

American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2026 | iPharmaCenter

ipharmaservices

3 days ago

Novo Nordisk to Slash U.S. List Prices for Semaglutide Portfolio from 2027 Amid Rising Competitive Pressure

Badari Andukuri

Feb 24

Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter

Badari Andukuri

Feb 24

CagriSema misses non‑inferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% | iPharmaCenter

ipharmaservices

Feb 23

Novartis Advances Remibrutinib Toward FDA Approval in Chronic Inducible Urticaria | iPharmaCenter

Badari Andukuri

Feb 20

Lilly's Taltz + Zepbound Combo Achieves Superior Psoriasis Clearance and Weight Loss in Phase 3b Trial | iPharmaCenter

Badari Andukuri

Feb 19

Amgen’s Uplizna wins European Commission approval for generalized myasthenia gravis | iPharmaCenter

ipharmaservices

Feb 17

GSK’s ultra‑long‑acting IL‑5 biologic Exdensur wins EU approval for severe asthma and CRSwNP | iPharmaCenter

ipharmaservices

Feb 17

The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter

Badari Andukuri

Feb 11

Lilly to Acquire Novel CAR-T Innovator Orna Therapeutics for $2.4 Billion to Advance In Vivo Cell Therapy Platform

ipharmaservices

Feb 10

EHSF 2026: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa

ipharmaservices

Feb 8

ACTRIMS 2026: Roche’s investigational therapy fenebrutinib shows breakthrough results in primary progressive multiple sclerosis (PPMS)

ipharmaservices

Feb 8

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

Badari Andukuri

Feb 7

From $31.60 to $25: How New PBS Rules Make Prescriptions More Affordable

Badari Andukuri

Feb 5

CDSCO Clears Durvalumab with FLOT as New Perioperative Standard for Gastric Cancer Patients in India | iPharmaCenter

ipharmaservices

Feb 2

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

Badari Andukuri

Jan 31

Roche’s GLP‑1/GIP receptor agonist CT‑388 demonstrated strong efficacy in patients with obesity | iPharmaCenter

ipharmaservices

Jan 27

NICE greenlights Dupixent as add-on therapy for uncontrolled COPD with raised eosinophils in England, marking first targeted biologic for this indication | iPharmaCenter

ipharmaservices

Jan 27

Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter

Badari Andukuri

Jan 26